Related Experiment Video
Updated: Jul 20, 2026

Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Wanli W Smith1, Zhong Pei, Haibing Jiang
1Department of Psychiatry, Division of Neurobiology, Johns Hopkins University School of Medicine, CMSC 8-121, 600 North Wolfe Street, Baltimore, Maryland 21287, USA. wsmith60@jhmi.edu
Abstract:
Mutations in the the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant Parkinson disease and some cases of sporadic Parkinson disease. Here we found that LRRK2 kinase activity was regulated by GTP via the intrinsic GTPase Roc domain, and alterations of LRRK2 protein that reduced kinase activity of mutant LRRK2 correspondingly reduced neuronal toxicity. These data elucidate the pathogenesis of LRRK2-linked Parkinson disease, potentially illuminate mechanisms of sporadic Parkinson disease and suggest therapeutic targets.
Insights
Mutations in leucine-rich repeat kinase-2 (LRRK2) cause Parkinson disease. Reduced LRRK2 kinase activity lessened neuronal toxicity, suggesting new therapeutic targets for Parkinson disease.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene are linked to autosomal-dominant and some sporadic forms of Parkinson disease.
- Understanding the molecular mechanisms underlying LRRK2's role in Parkinson disease pathogenesis is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the regulatory mechanisms of LRRK2 kinase activity.
- To determine the relationship between LRRK2 kinase activity and neuronal toxicity in Parkinson disease models.
Main Methods:
- Biochemical assays to study LRRK2 kinase activity regulation.
- Analysis of LRRK2 protein alterations and their impact on neuronal toxicity.
Main Results:
- LRRK2 kinase activity is regulated by GTP through its intrinsic GTPase Roc domain.
- Modifications to LRRK2 that decrease its kinase activity also reduce neuronal toxicity associated with mutant LRRK2.
Conclusions:
- The GTPase activity of the LRRK2 Roc domain is a key regulator of its kinase function.
- Reducing LRRK2 kinase activity represents a potential therapeutic strategy for LRRK2-linked Parkinson disease.
- These findings may also shed light on the mechanisms of sporadic Parkinson disease.
More Related Videos
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Lysosomal Hydrolases

